# Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

> **NCT00602576** · PHASE2 · COMPLETED · sponsor: **Abramson Cancer Center at Penn Medicine** · enrollment: 169 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** temozolomide

## Key facts

- **NCT ID:** NCT00602576
- **Lead sponsor:** Abramson Cancer Center at Penn Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-01
- **Primary completion:** 2008-12-21
- **Final completion:** 2009-07-26
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00602576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00602576, "Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00602576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*